Cancer is a genetic disease driven by mutations in genes that convert normal cells into cancer cells. Cancer-specific differences may include changes in the genome sequence, changes in the copy number of specific genes , and/or rearrangements or joining together of sequences in the genome. Personal Genome Diagnostics (PGDx) sequences the most important cancer genes for mutations that may provide the insight needed to best manage your patient's cancer.

CANCERSELECT™ - Target cancer gene sequencing approach

Targeted cancer gene analysis utilizes a panel for the detection of genetic alterations in 88 well-characterized cancer genes, having either approved-therapies, or active clinical trials. These genes are of high clinical and biologic importance and are screened using next generation sequencing at extremely high coverage to identify point mutations, copy number alterations, and rearrangements. Further in-depth computational analyses, such as, digital karyotyping, PARE, and other approaches, allow for the identification of oncogenic mutations.

CANCERCOMPLETE™ sequencing approach

CANCERCOMPLETE™ utilizes exome capture to selectively analyze only the coding regions of the genome. This approach allows the coding regions, the ‘exome’, to be sequenced at high coverage and allows for the reliable identification of sequence mutations and copy number alterations. Additionally, regions frequently mutated in cancer (88 genes included in the CANCERSELECT™ test) are analyzed at high coverage to identify point mutations, copy number alterations, and rearrangements.

How can these tests help my patients?

Information about the presence of particular mutations can help you in making treatment recommendations. Information that can be obtained from targeted sequencing and mutation analysis may include prognostic indicators, improved disease classification, additional therapies, or relevant clinical trials. 


[accordion][accordion-item title="How do I order a test?"]Please contact us and let us know if you would like to order a test for a patient. One of our representatives will get in touch with you and advise on the workflow, and provide the necessary forms and sample collection kits. Once the samples have been collected, we will coordinate the shipment of the sample to the laboratory. Once testing is completed, the report will be sent to you. [/accordion-item][accordion-item title="How do I prepare the samples for testing?"] Download the PGDx Sample Preparation Information sheet here. [/accordion-item][accordion-item title="How long does it take?"]The anticipated turnaround time is 4 weeks for the CANCERSELECT™ and 7 weeks for CANCERCOMPLETE™. [/accordion-item][accordion-item title="Who is CANCERSELECT™ & CANCERCOMPLETE™ appropriate for?"]This test is suitable for any patient with a cancer diagnosis that has been confirmed with a biopsy, but typically it is used for later stage cancer patients who have exhausted first line treatment. [/accordion-item][/accordion]